What type of study is this?

September 10, 2025Blood AdvancesOpen Access

Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial

View Full Paper

Ask AI

Bookmark

Authors

FSFebe SmitsDutch Cancer Society KGKaz GroenAmsterdam Neuroscience MLMark‐David LevinAlbert Schweitzer Hospital

Discussion

Member takes

Implication

Long-term follow-up data reveals frailty assessments improve understanding of patient outcomes in those with multiple myeloma, suggesting need for better definitions.

Key Points

Frailty significantly influences outcomes in older patients with multiple myeloma, not age alone.
Median progression-free survival was recorded at 13.8 months and overall survival at 34.0 months.
Patients' frailty was assessed using the International Myeloma Working Group Frailty Index (IMWG-FI) during the HOVON 143 trial.
Findings indicate the importance of refining frailty definitions to better identify patients at risk of early mortality.

Cite This Study

Smits et al. (2025) studied this question.

synapsesocial.com/papers/68c1ce7054b1d3bfb60f5bc3 https://doi.org/10.1182/bloodadvances.2025017394

View Full Paper

Ask AI

Bookmark

Implication

Long-term follow-up data reveals frailty assessments improve understanding of patient outcomes in those with multiple myeloma, suggesting need for better definitions.

Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider